Novanta Inc (NOVT) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally.
Total Cash From Operating Activities Chart for Novanta Inc
Novanta Inc (NOVT) operating cash flow for FY2025 was USD 64.1M, a -59.6% change from FY2024. Novanta Inc's operating cash flow moved from USD -7.0M in 1998 to USD 64.1M in 2025 over 27 years. Operating cash flow compound annual growth rate: 5-year CAGR of -14.5%, 10-year CAGR of 6.7%, 20-year CAGR of 13.8%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $5.64B
- Implied Share Price
- $149.10
- Enterprise Value
- $5.21B
- Revenue (TTM)
- $1.03B
- EBITDA
- $180.95M
- Profit Margin
- 6.00%
- Trailing P/E
- 94.37
- Forward P/E
- 8.39
- Price/Book (MRQ)
- 3.38
- Price/Sales (TTM)
- 5.53
- EV/EBITDA
- 27.69
- EV/Revenue
- 4.88
- Dividend Yield
- —
- Book Value
- $42.74
- Free Cash Flow (FY2025)
- $48.43M
- Free Cash Flow Yield
- 0.86%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.